Syndivia, a Strasbourg, France-based research-driven biotechnology company focused on the development of new therapeutic modalities for cancers, raised €2m in deep tech financing from Bpifrance.
The proceeds will be used to further fund the advancement of one company’s drug candidate towards the clinic.
Led by Sasha Koniev, CEO, Syndivia is a biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a specific targeting of the tumor microenvironment and anatomical hallmarks of solid tumors.
FinSMEs
10/03/2020